We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. Revenues came in at $735.9 million, beating the Zacks Consensus Estimate of $725.3 million. Revenues rose 20% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The reported number represents a change of +4.9% year over year. Revenues- Unituxin- U.S. $61.80 million versus the two-analyst average estimate of $49.86 million. Revenues- Adcirca: $4.70 million ...

While DANYELZA has shown modest growth in the U.S. market, it faces competition from established products like United Therapeutics (NASDAQ:UTHR)' Unituxin. Y-mAbs' SADA platform represents a ...

1101 Spring St. will be the home of the Dinutuximab-Dedicated Oncology Medical & Analytical Laboratory (DDOMAL) that will increase the company’s capacity to produce Unituxin. UT bought the property in ...